Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 16/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2964468 | 0.85 | SMN1; SMN2 (0.48) | PTPN1 | |
| SCHEMBL2956449 | 0.82 | SMN1; SMN2 (0.48) | PTPN1HTTALDH1A1POLBL3MBTL1 | |
| Hydrochloric Acid SCHEMBL7980948 | 0.80 | PTPN1 (0.51) | PTPN1 | |
| SCHEMBL2956456 | 0.77 | RAB9A (0.48) | HTTKDM4EALDH1A1POLBKMT2A | |
| SCHEMBL2958592 | 0.77 | RAB9A (0.43) | PTPN1ALDH1A1POLBKMT2A | |
| SCHEMBL2954632 | 0.76 | PTPN1 (0.43) | PTPN1L3MBTL1 | |
| SCHEMBL2961088 | 0.74 | ATM (0.43) | PTPN1HTTMEN1ALDH1A1POLB | |
| Oxalic Acid SCHEMBL10753837 | 0.72 | PTPN1 (0.54) | PTPN1KDM4EALDH1A1 | |
| Oxalic Acid SCHEMBL10757087 | 0.70 | PTPN1 (0.52) | PTPN1KDM4EALDH1A1 | |
| SCHEMBL27676748 | 0.70 | FABP4 (0.38) | PTPN1ALDH1A1POLBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772237-B2 | Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives | CEPHALON FRANCE (FR) | 2010-08-10 | — | — | US | disclosed |
| US-20090105241-A1 | THIO-SUBSTITUTED TRICYCLIC AND BICYCLIC AROMATIC METHANESULFINYL DERIVATIVES | CEPHALON FRANCE (FR) | 2009-04-23 | — | — | US | disclosed |
| US-7476690-B2 | Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives | CEPHALON FRANCE (FR) | 2009-01-13 | — | — | US | disclosed |
| US-20060241119-A1 | Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives | CEPHALON FRANCE (FR) | 2006-10-26 | — | — | US | disclosed |
| US-7119214-B2 | Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives | CEPHALON FRANCE (FR) | 2006-10-10 | — | — | US | disclosed |
| US-20050282821-A1 | Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives | CEPHALON FRANCE (FR) | 2005-12-22 | — | — | US | disclosed |
| EP-1589016-A1 | Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives | CEPHALON FRANCE (FR) | 2005-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282821-A1 | Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives | HTR1A, HTR2A, HTR5A | PTPN1 1143/4885HTT 90/4885KDM4E 1472/4885 |
| US-20060241119-A1 | Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives | HTR1A, HTR2A, HTR5A | PTPN1 1143/4885HTT 90/4885KDM4E 1472/4885 |
| US-20090105241-A1 | THIO-SUBSTITUTED TRICYCLIC AND BICYCLIC AROMATIC METHANESULFINYL DERIVATIVES | HTR1A, HTR2A, HTR5A | PTPN1 1143/4885HTT 90/4885KDM4E 1472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.